Fries Fabian Norbert, Náray Annamária, Munteanu Cristian, Stachon Tanja, Lagali Neil, Seitz Berthold, Käsmann-Kellner Barbara, Szentmáry Nóra
Dr. Rolf M. Schwiete Center for Limbal Stem Cell and Aniridia Research, Saarland University, Homburg/Saar, Germany.
Department of Ophthalmology, Saarland University Medical Center, Homburg/Saar, Germany.
Klin Monbl Augenheilkd. 2025 May;242(5):578-583. doi: 10.1055/a-2194-1580. Epub 2023 Oct 18.
Congenital aniridia is a severe malformation of almost all eye segments. Aniridia-associated keratopathy (AAK) and secondary glaucoma, which occur in more than 50% of affected individuals, are typically progressive and pose a high risk of blindness for patients with congenital aniridia. Our aim was to investigate the effect of glaucoma treatment on AAK in patients of the Homburg Aniridia Center.
Our retrospective monocentric study included patients who underwent a comprehensive ophthalmological examination at the Homburg Aniridia Center between June 2003 and January 2022.
There were 556 eyes of 286 subjects (20.1 ± 20.1 years; 45.5% males) included. In 307 (55.2%) eyes of 163 subjects (27.5 ± 16.3 years; 43.1% males), glaucoma was present at the time of examination. The mean intraocular pressure in the glaucoma group was 19.0 mmHg (± 8.0), while in the non-glaucoma group, it was 14.1 mmHg (± 3.6) (p < 0.001). In the glaucoma group, 68 patients used antiglaucomatous topical monotherapy, 51 patients used 2 agents, 41 patients used 3 agents, 7 patients used quadruple therapy, and 140 did not use topical therapy (e.g., after pressure-lowering surgery, pain-free end-stage glaucoma, or incompliance). Patients were classified according to the following stages of AAK: Stage 0 (96 eyes [17.2%], no keratopathy), Stage 1 (178 eyes [32.0%]), Stage 2 (107 eyes [19.2%]), Stage 3 (67 eyes [12.0%]), Stage 4 (62 eyes [11.1%]), Stage 5 (45 eyes [8.0%]). The mean stage of AAK was 1.4 (1.2 - 1.5) in the group without eye drops, 1.9 (1.5 - 2.2) in the group with monotherapy, 1.8 (1.5 - 2.1) in the group with 2 drugs, 1.9 (1.5 - 2.2) in the group with 3 drugs, 3.4 (2.3 - 4.6) in the group with 4 drugs, and 3.3 (3.1 - 3.6) after antiglaucomatous surgery. The stage of AAK was significantly positively correlated with the number of pressure-lowering eye drops (p < 0.05) and prior pressure-lowering surgery (p < 0.05). Prostaglandin analogues were not correlated with a higher AAK stage compared to the other drug groups.
At the Homburg Aniridia Center, patients using topical antiglaucomatous quadruple therapy or who had previously undergone antiglaucomatous surgery had by far the highest AAK stage. The different drug groups had no influence on the AAK stage.
先天性无虹膜是几乎累及所有眼段的严重畸形。无虹膜相关性角膜病变(AAK)和继发性青光眼在超过50%的患者中出现,通常呈进行性发展,给先天性无虹膜患者带来了高失明风险。我们的目的是研究洪堡无虹膜中心患者青光眼治疗对AAK的影响。
我们的回顾性单中心研究纳入了2003年6月至2022年1月期间在洪堡无虹膜中心接受全面眼科检查的患者。
共纳入286名受试者的556只眼(年龄20.1±20.1岁;男性占45.5%)。在163名受试者(年龄27.5±16.3岁;男性占43.1%)的307只眼(55.2%)中,检查时存在青光眼。青光眼组的平均眼压为19.0 mmHg(±8.0),而非青光眼组为14.1 mmHg(±3.6)(p<0.001)。在青光眼组中,68例患者使用抗青光眼局部单一疗法,51例患者使用两种药物,41例患者使用三种药物,7例患者使用四联疗法,140例未使用局部疗法(如降压手术后、无痛终末期青光眼或依从性差)。患者根据AAK的以下阶段进行分类:0期(96只眼[17.2%],无角膜病变),1期(178只眼[32.0%]),2期(107只眼[19.2%]),3期(67只眼[12.0%]),4期(62只眼[11.1%]),5期(45只眼[8.0%])。未使用眼药水组的AAK平均阶段为1.4(1.2 - 1.5),单一疗法组为1.9(1.5 - 2.2),两种药物组为1.8(1.5 - 2.1),三种药物组为1.9(1.5 - 2.2),四种药物组为3.4(2.3 - 4.6),抗青光眼手术后为3.3(3.1 - 3.6)。AAK阶段与降压眼药水的使用次数(p<0.05)和既往降压手术(p<0.05)呈显著正相关。与其他药物组相比,前列腺素类似物与更高的AAK阶段无关。
在洪堡无虹膜中心,使用局部抗青光眼四联疗法或既往接受过抗青光眼手术的患者的AAK阶段最高。不同药物组对AAK阶段没有影响。